Table 1.
Baseline patient characteristics and ICM implant primary indications (N = 20)
| Age (y) | 68 ± 12 |
|---|---|
| Female | 10 (50) |
| Insertable cardiac monitor indication | |
| Unexplained syncope Risk for cardiac arrhythmias Atrial fibrillation Cryptogenic stroke |
15 (75)3 (15)1 (5)1 (5) |
| Hypertension | 10 (50) |
| Diabetes | 5 (25) |
| Stroke | 3 (15) |
| Heart failure | 1 (5) |
| Atrial fibrillation | 6 (30) |
| Ventricular tachycardia | 3 (15) |
| Coronary artery disease | 2 (10) |
| History of cerebral ischemia, vascular disease, previous myocardium infarction, peripheral arterial disease, or aortic plaque | 8 (40) |
| CHA2DS2VASc score | 3.0 ± 2.2 |
| Oral anticoagulation | 2 (10) |
| Platelet inhibitors | 10 (50) |
| Class III antiarrhythmic drugs | 2 (10) |
| Beta-blockers | 6 (30) |
| Calcium channel blockers | 2 (10) |
| Renin–angiotensin inhibitors | 9 (45) |
| Statins | 7 (35) |
| Diuretics | 5 (25) |
Values are given as mean ± SD or n (%) unless otherwise indicated.
ICM = insertable cardiac monitor.